FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
|Videos|September 29, 2020
Practical Management of Early Stage HER2+ Breast Cancer
Author(s)Staff
Advertisement
Nurse practitioners provide insight on issues surrounding the administration of dual HER2-targeted therapy in the neoadjuvant/adjuvant setting and counseling patients on common AEs associated with trastuzumab-pertuzumab for the treatment of HER2+ breast cancer.
Advertisement
Related to this article
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
Oncology nurse April Fowler shares her personal stage 4 cancer journey, reflecting on clinical empathy, patient advocacy, and oncology endurance.
ANA President Jennifer Mensik Kennedy outlines systemic nurse fatigue mitigation policies, emphasizing patient safety and acuity across oncology care.
A nurse-led support program significantly reduces death anxiety in women with breast cancer on hormonal therapy, study finds.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Advisory Panel Votes to Approve GRAIL Galleri MCED Screening Test
2
Psychedelic Medicine in Cancer Care: What Nursing Teams Need to Know
3
Oncology Nurse Shares Insights From Her Stage 4 Breast Cancer Journey
4
Reframing Nurse Fatigue as Systemic Safety Risk
5